Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 1.28
-1.56 %
$ 139 M
Market Cap
-0.75
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Aclaris Therapeutics, Inc.
| Net Income | -132 M |
| Depreciation & Amortization | 807 K |
| Capital Expenditures | -121 K |
| Stock-Based Compensation | 10.9 M |
| Change in Working Capital | 10.9 M |
| Others | 105 M |
| Free Cash Flow | -20.2 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||||||
| Net Income | (132.1) | (88.5) | (86.9) | (90.9) | (51.0) | (161.4) | (132.7) | (68.5) | (48.1) | (20.6) | (8.5) | (5.2) |
| Depreciation & Amortization | 0.8 | 0.9 | 0.8 | 0.9 | 1.3 | 6.4 | 1.9 | 0.4 | 0.1 | 90 K | 12 K | 11 K |
| Deferred Income Tax | 0 | (0.4) | 0 | 0.8 | (0.2) | 44.3 | 0 | (1.8) | 0.2 | 0.3 | 0 | 0 |
| Stock Based Compensation | 10.9 | 20.5 | 15.0 | 14.1 | 11.2 | 16.2 | 20.1 | 14.4 | 6.1 | 0.9 | 27 K | 0 |
| Other Operating Activities | 89.4 | (20.3) | 4.7 | 24.3 | 2.4 | 0.7 | 0.6 | 10.7 | 2.8 | 5 K | 1 K | 3 K |
| Change in Working Capital | 10.9 | 9.4 | (1.2) | (1.3) | (2.4) | (2.7) | 9.4 | 0.9 | 4.3 | (1.1) | 0.8 | 0.3 |
| Cash From Operations | (20.1) | (78.3) | (67.6) | (52.1) | (38.6) | (96.4) | (100.8) | (54.7) | (34.6) | (20.4) | (7.6) | (4.9) |
| INVESTING CASH FLOW | ||||||||||||
| Capital Expenditures | (0.1) | (1.3) | (0.6) | (0.3) | (0.5) | (1.6) | (1.4) | (1.2) | (0.2) | (0.5) | (0.4) | 0 |
| Other Items | (69.6) | 47.5 | 13.2 | (167.3) | 6.8 | 107.3 | 10.7 | (54.5) | (61.7) | (76.4) | (1.4) | (4.5) |
| Cash From Investing Activities | (69.8) | 46.2 | 12.6 | (167.6) | 6.4 | 105.7 | 9.4 | (55.7) | (61.9) | (77.0) | (1.8) | (4.5) |
| FINANCING CASH FLOW | ||||||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | (11.5) | 10.8 | (30.5) | 29.3 | 78 K | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.4) | 86 K | 0.1 | (1.7) | 7.6 | 0.2 | (1.2) | 0.2 | 0.1 | 39.9 | 10.6 | 0 |
| Cash From Financing Activities | 74.5 | 26.7 | 72.9 | 225.1 | 18.4 | (30.3) | 128.3 | 100.4 | 116.8 | 96.4 | 10.6 | 0 |
| CHANGE IN CASH | ||||||||||||
| Net Change In Cash | (15.3) | (5.4) | 17.9 | 5.3 | (13.9) | (21.1) | 36.8 | (10.0) | 20.3 | (0.9) | 1.2 | (9.5) |
| FREE CASH FLOW | ||||||||||||
| Free Cash Flow | (20.2) | (79.6) | (68.2) | (52.4) | (39.1) | (98.1) | (102.2) | (55.9) | (34.8) | (20.9) | (8.1) | (4.9) |